Your browser doesn't support javascript.
loading
Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer.
Li, Shuai; Liu, Shengwu; Deng, Jiehui; Akbay, Esra A; Hai, Josephine; Ambrogio, Chiara; Zhang, Long; Zhou, Fangyu; Jenkins, Russell W; Adeegbe, Dennis O; Gao, Peng; Wang, Xiaoen; Paweletz, Cloud P; Herter-Sprie, Grit S; Chen, Ting; Gutiérrez-Quiceno, Laura; Zhang, Yanxi; Merlino, Ashley A; Quinn, Max M; Zeng, Yu; Yu, Xiaoting; Liu, Yuting; Fan, Lichao; Aguirre, Andrew J; Barbie, David A; Yi, Xianghua; Wong, Kwok-Kin.
Afiliación
  • Li S; Department of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
  • Liu S; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Deng J; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Akbay EA; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Hai J; Department of Pathology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas; Simmons Comprehensive Cancer Center, Dallas, Texas.
  • Ambrogio C; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Zhang L; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Zhou F; Department of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
  • Jenkins RW; Department of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
  • Adeegbe DO; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Gao P; Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Wang X; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Paweletz CP; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Herter-Sprie GS; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Chen T; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Gutiérrez-Quiceno L; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Zhang Y; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Merlino AA; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
  • Quinn MM; Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
  • Zeng Y; Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
  • Yu X; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Liu Y; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Fan L; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Aguirre AJ; Department of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
  • Barbie DA; Department of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
  • Yi X; Department of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
  • Wong KK; Department of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Clin Cancer Res ; 24(19): 4854-4864, 2018 10 01.
Article en En | MEDLINE | ID: mdl-29945997
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Bencimidazoles / Proteína p53 Supresora de Tumor / Proteínas Proto-Oncogénicas p21(ras) / Quinasa 1 de Quinasa de Quinasa MAP / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Bencimidazoles / Proteína p53 Supresora de Tumor / Proteínas Proto-Oncogénicas p21(ras) / Quinasa 1 de Quinasa de Quinasa MAP / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: China